In addition, doxorubicin has been shown to increase MDR1 in B-cell lymphoma cells through activation of the Mitogen Activated Protein Kinase/Extracellular-signal-Regulated Kinases (MAPK/ERK) signaling pathway [54]. The gene discussed is ABCB1; the disease is B-cell non-Hodgkin lymphoma.